BRIEF published on 07/06/2026 at 22:10, 2 months 10 days ago Abivax Completes its $920 Million Public Offering Biotechnology Actions Funding Abivax Public Offering
BRIEF published on 07/06/2026 at 22:10, 2 months 10 days ago Abivax Secures $920 Million in Public Offering Biotechnology Abivax Ulcerative Colitis Public Offering American Depositary Shares
PRESS RELEASE published on 07/06/2026 at 22:05, 2 months 10 days ago Abivax Announces Closing of $920 Million Public Offering Abivax closes $920 million public offering, strengthening financial position. Proceeds to support operations until Q4 2029. Leerink Partners, Morgan Stanley, Piper Sandler, Guggenheim Securities involved in the offering Financial Position Abivax Morgan Stanley Public Offering Leerink Partners
BRIEF published on 07/02/2026 at 08:05, 2 months 14 days ago Abivax successfully concludes an ADS offer Biotechnology Abivax Offer Ads Investments
BRIEF published on 07/02/2026 at 08:05, 2 months 14 days ago Abivax's Offering Yields $920M Following Over-Allotment Exercise Biotechnology Abivax Obefazimod Capital Increase ADS Offering
PRESS RELEASE published on 07/02/2026 at 08:00, 2 months 14 days ago Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) Abivax announces full exercise of underwriters' option to purchase additional ADSs, bringing gross proceeds of offering to $920M (€807M) Biotechnology Abivax Capital Increase Underwriters ADSs
BRIEF published on 07/01/2026 at 15:17, 2 months 15 days ago Abivax resumes trading of its shares on Euronext Paris Euronext Paris Biotechnology Actions Abivax Suspension
BRIEF published on 07/01/2026 at 15:17, 2 months 15 days ago Abivax relaunches trading of its shares on Euronext Paris Euronext Paris Ordinary Shares Abivax Inflammatory Diseases American Depositary Shares
BRIEF published on 07/01/2026 at 14:59, 2 months 15 days ago Abivax Resumes Trading on Euronext Paris Euronext Paris Biotechnology Abivax Ulcerative Colitis American Depositary Shares
PRESS RELEASE published on 07/01/2026 at 14:54, 2 months 15 days ago Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces resumption of trading for its ordinary shares on Euronext Paris following a public offering in the United States Euronext Paris Abivax Public Offering Phase 3 Clinical Trials Trading Resumption
Published on 09/16/2026 at 23:45, 2 hours 42 minutes ago Galway Metals Settles Claim by Former Employee with Cash and Share Payments
Published on 09/16/2026 at 21:30, 4 hours 57 minutes ago Torq Completes $1.7 Million Private Placement
Published on 09/16/2026 at 16:55, 9 hours 32 minutes ago CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 11 hours 27 minutes ago 2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 12 hours 27 minutes ago Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 23:45, 2 hours 42 minutes ago WESCAN GOLDFIELDS COMMENCES UAV MAGNETIC AND LIDAR SURVEYS AT MUNRO LAKE PROJECT
Published on 09/16/2026 at 22:33, 3 hours 53 minutes ago EQS-Adhoc: Bilfinger adjusts outlook for 2026 and resolves program “Agile”
Published on 09/16/2026 at 21:15, 5 hours 12 minutes ago Gastech 2026 in Bangkok Converts Global Energy Ambition into Billions of Dollars in Deals
Published on 09/16/2026 at 20:27, 5 hours 59 minutes ago EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 19:05, 7 hours 21 minutes ago EcoFlow to showcase its open home energy ecosystem at Solar & Storage Live Zurich 2026
Published on 09/16/2026 at 17:45, 8 hours 42 minutes ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 19 hours 27 minutes ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 8 hours ago Report on the Combined General Meeting of the 10th of September 2026
